| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Sirtuin modulator 3 targets sirtuins, a family of NAD+-dependent deacetylases that play critical roles in cellular regulation, metabolism, and aging. As an N-phenyl benzamide derivative, the compound modulates sirtuin activity, affecting downstream signaling pathways involved in DNA repair, inflammation, and energy homeostasis.
|
|---|---|
| ln Vitro |
Sirtuin modulator 3 demonstrates in vitro activity as a sirtuin modulator. The compound has been shown to influence sirtuin activity in biochemical assays. Its activity is typically assessed in enzymatic assays measuring sirtuin deacetylase activity in the presence of the compound.
|
| ln Vivo |
In vivo activity of sirtuin modulator 3 has not been extensively documented. Its modulation of sirtuin activity, which is implicated in aging and cellular regulation, suggests potential for in vivo studies in models of aging, metabolic disorders, and inflammation. Further in vivo studies are needed to evaluate its efficacy and safety.
|
| Enzyme Assay |
In vitro enzyme assays for sirtuin modulator 3 involve measuring its modulation of sirtuin deacetylase activity. The assay typically uses purified recombinant sirtuin enzymes and fluorogenic peptide substrates containing acetylated lysine residues. Deacetylase activity is measured by detecting the release of fluorescent products in the presence of the compound.
|
| Cell Assay |
In vitro cellular assays for sirtuin modulator 3 involve treating cells with varying concentrations of the compound and measuring changes in protein acetylation levels using Western blotting or ELISA. Cellular effects such as proliferation, apoptosis, or metabolic changes can be assessed using standard cell-based assays.
|
| Animal Protocol |
In vivo animal experiments for sirtuin modulator 3 are not extensively documented. If used in animal models, typical protocols would involve administering the compound to models of aging, metabolic disorders, or inflammation and evaluating efficacy by measuring biomarkers of sirtuin activity and disease progression.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for sirtuin modulator 3 are limited. The compound has a molecular weight of 417.46 and a molecular formula of C24H23N3O4. It is soluble in DMSO at 250 mg/mL (598.86 mM) with ultrasonic. Powder should be stored at -20°C for up to 3 years; solutions at -20°C for up to 6 months. Its ADME properties have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for sirtuin modulator 3 are limited. As a research compound, comprehensive toxicological studies have not been reported. The compound is intended for research use only and is not for human therapeutic application. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Sirtuin modulator 3 (CAS#: 708995-11-3) has the molecular formula C24H23N3O4 and a molecular weight of 417.46. It is an N-phenyl benzamide derivative that functions as a sirtuin modulator. Purity is >98%. The compound is used in research on sirtuin biology, aging, and cellular regulation.
|
| Molecular Formula |
C24H23N3O4
|
|---|---|
| Molecular Weight |
417.46
|
| Exact Mass |
417.168
|
| CAS # |
708995-11-3
|
| PubChem CID |
983446
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.611
|
| LogP |
4.27
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
591
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC2=NC(=CN2C=C1)C3=CC(=CC=C3)NC(=O)C4=CC(=C(C(=C4)OC)OC)OC
|
| InChi Key |
ZCNAQCKPWWPHDY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H23N3O4/c1-15-8-9-27-14-19(26-22(27)10-15)16-6-5-7-18(11-16)25-24(28)17-12-20(29-2)23(31-4)21(13-17)30-3/h5-14H,1-4H3,(H,25,28)
|
| Chemical Name |
3,4,5-trimethoxy-N-[3-(7-methylimidazo[1,2-a]pyridin-2-yl)phenyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (598.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3954 mL | 11.9772 mL | 23.9544 mL | |
| 5 mM | 0.4791 mL | 2.3954 mL | 4.7909 mL | |
| 10 mM | 0.2395 mL | 1.1977 mL | 2.3954 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
